{"title":"Enhancing the radionuclide theranostic concept through the radiohybrid approach.","authors":"Tobias Krönke, Klaus Kopka, Constantin Mamat","doi":"10.1039/d4md00591k","DOIUrl":null,"url":null,"abstract":"<p><p>Radionuclide theranostics - a fast-growing emerging field in radiopharmaceutical sciences and nuclear medicine - offers a personalised and precised treatment approach by combining diagnosis with specific and selective targeted endoradiotherapy. This concept is based on the application of the same molecule, labelled with radionuclides possessing complementary imaging and therapeutic properties, respectively. In radionuclide theranostics, radionuclide pairs consisting of the same element, such as <sup>61/64</sup>Cu/<sup>67</sup>Cu, <sup>203</sup>Pb/<sup>212</sup>Pb or <sup>123/124</sup>I/<sup>131</sup>I are of significant interest due to their identical chemical and pharmacological characteristics. However, such \"true matched pairs\" are seldom, necessitating the use of complementary radionuclides from different elements for diagnostics and endoradiotherapy with similar chemical characteristics, such as <sup>99m</sup>Tc/<sup>186/188</sup>Re, <sup>68</sup>Ga/<sup>177</sup>Lu or <sup>68</sup>Ga/<sup>225</sup>Ac. Corresponding combinations of such two radionuclides in one and the same radioconjugate is referred to as a \"matched pair\". Notably, the pharmacological behavior remains consistent across both diagnostic and therapeutic applications with \"true matched pairs\", which may differ for \"matched pairs\". As \"true matched pairs\" of theranostic radioisotopes are rare and that some relevant radionuclides do not fit with the diagnostic or therapeutic counterpart, the radionuclide theranostic concept can be expanded and improved by the introduction of the radiohybrid approach. Radiohybrid (rh) ligands represent a new class of radiopharmaceutical bearing two different positions for the introduction of a (radio)metal and (radio)halogen in one molecule, which can be then used for both therapeutic and diagnostic purposes. The following review will give an insight into recent developments of this approach.</p>","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11606402/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"RSC medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1039/d4md00591k","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Radionuclide theranostics - a fast-growing emerging field in radiopharmaceutical sciences and nuclear medicine - offers a personalised and precised treatment approach by combining diagnosis with specific and selective targeted endoradiotherapy. This concept is based on the application of the same molecule, labelled with radionuclides possessing complementary imaging and therapeutic properties, respectively. In radionuclide theranostics, radionuclide pairs consisting of the same element, such as 61/64Cu/67Cu, 203Pb/212Pb or 123/124I/131I are of significant interest due to their identical chemical and pharmacological characteristics. However, such "true matched pairs" are seldom, necessitating the use of complementary radionuclides from different elements for diagnostics and endoradiotherapy with similar chemical characteristics, such as 99mTc/186/188Re, 68Ga/177Lu or 68Ga/225Ac. Corresponding combinations of such two radionuclides in one and the same radioconjugate is referred to as a "matched pair". Notably, the pharmacological behavior remains consistent across both diagnostic and therapeutic applications with "true matched pairs", which may differ for "matched pairs". As "true matched pairs" of theranostic radioisotopes are rare and that some relevant radionuclides do not fit with the diagnostic or therapeutic counterpart, the radionuclide theranostic concept can be expanded and improved by the introduction of the radiohybrid approach. Radiohybrid (rh) ligands represent a new class of radiopharmaceutical bearing two different positions for the introduction of a (radio)metal and (radio)halogen in one molecule, which can be then used for both therapeutic and diagnostic purposes. The following review will give an insight into recent developments of this approach.